|
| 37099733 | Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis. | JCO Precis Oncol | 2023 |
| 37609132 | Stress, Isolation, and Sleep Quality among Breast Cancer Survivors throughout the COVID-19 Pandemic: A Longitudinal Study in a Multi-Ethnic Cohort. | | 2023 |
| 37676974 | Racial/Ethnic Disparities in Telemedicine Utilization and Satisfaction Among Breast Cancer Patients During the COVID-19 Pandemic: A Mixed-Methods Analysis. | | 2023 |
| 37795405 | Ten years survival results of randomized study comparing weekly . triweekly cisplatin with concurrent radiation in locally advanced carcinoma cervix. | | 2023 |
| 37611646 | Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer. | | 2023 |
| 36585450 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | Nat Cancer | 2023 |
| 37149628 | Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients. | | 2023 |
| 37146605 | Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. | Cancer Cell | 2023 |
| 37462224 | Demographic and Clinical Characteristics Associated With Familiarity, Interest, and Use of Integrative Therapies Among Patients With Breast Cancer. | | 2023 |
| 36821125 | Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. | | 2023 |
| 37195235 | A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. | Clin Cancer Res | 2023 |
| 37120458 | The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer. | | 2023 |
| 37059742 | Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence. | | 2023 |
| 36995716 | Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer. | | 2023 |
| 36993723 | The Impact of Race and Age on Response to Neoadjuvant Therapy and Long-Term Outcomes in Black and White Women with Early-Stage Breast Cancer. | | 2023 |
| 37231433 | Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. | Breast Cancer Res | 2023 |
| 36534524 | Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective Trial. | Clin Cancer Res | 2023 |
| 35173164 | Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. | NPJ Breast Cancer | 2022 |
| 35513244 | Treatment Efficacy Score-continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials. | Ann Oncol | 2022 |
| 35834065 | Clinical trials of immunotherapy in triple-negative breast cancer. | Breast Cancer Research and Treatment | 2022 |
| 36139594 | Diffusion-Weighted MRI for Predicting Pathologic Complete Response in Neoadjuvant Immunotherapy. | Cancers (Basel) | 2022 |
| 36268941 | GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer. | Future Oncol | 2022 |
| 36063220 | Highly accurate response prediction in high-risk early breast cancer patients using a biophysical simulation platform. | Breast Cancer Research and Treatment | 2022 |
| 35351365 | Differences Between Ipsilateral and Contralateral Early Parenchymal Enhancement Kinetics Predict Response of Breast Cancer to Neoadjuvant Therapy. | Academic Radiology | 2022 |
| 36408586 | The evolving therapeutic landscape of antibody-drug conjugates in breast cancer. | Expert Review of Anticancer Therapy | 2022 |
| 36456573 | Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer. | NPJ Breast Cancer | 2022 |
| 34569400 | The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. | Expert Opinion on Investigational Drugs | 2022 |
| 34910554 | BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer. | J Clin Oncol | 2022 |
| 34529000 | Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial. | JAMA Oncol | 2021 |
| 34077270 | Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. | J Clin Oncol | 2021 |
| 34016993 | Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study. | NPJ Breast Cancer | 2021 |
| 34120223 | Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). | Breast Cancer Res Treat | 2021 |
| 34285218 | The impact of site-specific digital histology signatures on deep learning model accuracy and bias. | Nature Communications | 2021 |
| 34168049 | Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. | Clin Cancer Res | 2021 |
| 33617937 | Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy. | Ann Oncol | 2021 |
| 33830407 | First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer. | Investigational New Drugs | 2021 |
| 34143979 | Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial. | Cancer Cell | 2021 |
| 34324366 | Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. | J Clin Oncol | 2021 |
| 33111220 | Racial disparities in survival outcomes among breast cancer patients by molecular subtypes. | Breast Cancer Res Treat | 2021 |
| 34741023 | Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2<sup>+</sup> breast cancer in the adaptively randomized I-SPY2 trial. | Nat Commun | 2021 |
| 34389617 | Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. | J Immunother Cancer | 2021 |
| 34611148 | Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. | NPJ Breast Cancer | 2021 |
| 33406056 | Novel therapies for triple-negative breast cancer. | Clinical Advances in Hematology and Oncology | 2020 |
| 32070401 | TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer. | Breast Cancer Res | 2020 |
| 32067545 | Atezolizumab for the treatment of breast cancer. | Expert Review of Anticancer Therapy | 2020 |
| 32053137 | Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. | JAMA Oncol | 2020 |
| 31822498 | TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR Metastatic Triple-Negative Breast Cancer. | Clinical Cancer Research | 2020 |
| 31662331 | TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer. | Clin Cancer Res | 2020 |
| 32031889 | MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial. | J Clin Oncol | 2020 |
| 32701140 | Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial. | JAMA Oncol | 2020 |